New combo therapy shows promise for Hard-to-Treat myeloma

NCT ID NCT03180736

Completed Disease control Sponsor: Stichting European Myeloma Network Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tested whether adding daratumumab to standard pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma live longer without their disease getting worse. 304 adults who had already tried lenalidomide and a proteasome inhibitor took part. The main goal was to compare progression-free survival between the two treatment groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daratumumab, pomalidomide, dexamethasone
What this could lead to: If successful, adding daratumumab could help people with multiple myeloma live longer without their cancer worsening.
What could go wrong: This is a completed phase 3 trial, but results may not apply to all patients. Daratumumab can cause infusion reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Ancona

Ancona, Italy
Anticancer Hospital of Thessaloniki "Theageneio"

Thessaloniki, Greece
Antwerpen

Antwerp, Belgium
Badalona

Badalona, Spain
Barcelona

Barcelona, Spain
Belgrade

Belgrade, Serbia
Bologna

Bologna, Italy
Brescia

Brescia, Italy
Brno

Brno, Czechia
Brussel

Brussels, Belgium
Capa

Çapa, Turkey (Türkiye)
Cebeci

Cebeli, Turkey (Türkiye)
Doctor Peset University Hospital Medical Centre

Valencia, Spain
Erasmus MC

Rotterdam, Netherlands
Freiburg

Freiburg im Breisgau, Germany
Gaziantep

Gaziantep, Turkey (Türkiye)
General Hospital of Athens "Evangelismos"

Athens, Greece
General University Hospital of Patras

Pátrai, Greece
Hamburg

Hamburg, Germany
Heidelberg

Heidelberg, Germany
Hospital Quirón Salud Madrid

Madrid, Spain
Hospital Universitario de la Princesa

Madrid, Spain
Izmir

Izmir, Turkey (Türkiye)
Kayseri

Kayseri, Turkey (Türkiye)
Kiel

Kiel, Germany
Milano

Milan, Italy
Odense

Odense, Denmark
Ostrava

Ostrava, Czechia
Praha 2

Prague, Czechia
Roma

Roma, Italy
Salamanca University Hospital

Salamanca, Spain
Schwerin

Schwerin, Germany
Torino

Torino, Italy
Tübingen

Tübingen, Germany
UZ Gent

Ghent, Belgium
University of Athens School of Medicine

Athens, Greece
VU MC

Amsterdam, Netherlands
Vejle

Vejle, Denmark
Würzburg

Würzburg, Germany
Yvoir

Yvoir, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.